URGN - UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
2024-03-14 20:13:09 ET
UroGen Pharma Ltd. (URGN)
Q4 2023 Earnings Conference Call
March 14, 2024, 10:00 AM ET
Company Participants
Vincent Perrone - Head of IR
Elizabeth Barrett - President and CEO
Mark Schoenberg - Chief Medical Officer
Dong Kim - CFO
Jeffrey Bova - Chief Commercial Officer
Silvio Pacheco - VP of Market Access
Conference Call Participants
Tara Bancroft - TD Cowen
Leland Gershell - Oppenheimer
Paul Choi - Goldman Sachs
Matt Kaplan - Ladenburg Thalmann
Presentation
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Full Year 2023 Earnings Call. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations. You may begin.
Vincent Perrone
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's full year 2023 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter and year ended December 31, 2023. The press release can be accessed on the Investors portion of our website at investors.urogen.com.
Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to JELMYTO, our ongoing and planned clinical trials, commercial and clinical milestones, market and revenue projections and opportunities, our commercialization strategy and expectation as well as potential future commercialization activities for UGN-102, if approved, anticipated data, regulatory filings and decisions, including UGN-102 potentially receiving a priority review UGN-102 being transformative and the major growth driver for UroGen have approved, future research and development efforts for UGN-103, UGN-104 and UGN-301, our corporate goals and 2024 financial guidance, among other things....
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript